1060811-62-2

Basic information

• Product Name: 4,6-dichloronicotinaldehyde
• Synonyms: 4,6-dichloronicotinaldehyde;4,6-Dichloropyridine-3-carbaldehyde;4,6-Dichloropyridine-3-carboxaldehyde;4,6-Dichloronicotinaldehyde(WXC01807)
• CAS NO: 1060811-62-2
• Molecular Formula: C₆H₃Cl₂NO
• Molecular Weight: 176
• Mol File: 1060811-62-2.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 268.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.488±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -1.17±0.10(Predicted)
• CAS DataBase Reference: 4,6-dichloronicotinaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloronicotinaldehyde(1060811-62-2)
• EPA Substance Registry System: 4,6-dichloronicotinaldehyde(1060811-62-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1060811-62-2(Hazardous Substances Data)

Usage

General Description

4,6-Dichloronicotinaldehyde is a chemical compound which is part of the Pyridine and derivatives class, specifically, it's a dialkylpyridine. Its molecular formula is C6H3Cl2NO and it has a molar mass of 192.00074 g·mol?1. It appears as a solid in its natural state, as a stable compound, but few details are available about its specific properties, such as its melting point, boiling point, or solubility. As implied by its name, it is a derivative of nicotinaldehyde, which is made by replacing two of the hydrogen atoms with chlorine. Due to the lack of publicly available data, it is unclear what this chemical is used for or its potential hazards.

Upstream product

• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 73998-95-5 2,4-dichloro-5-hydroxymethylpyridine 
• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 73027-79-9 4,6-dichloro-nicotinic acid 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 

Downstream Products

• 1558302-68-3 6-chloro-1-methyl-1H-pyrazolo[4,3-c]pyridine 
• 1588424-37-6 C₂₁H₁₄F₃N₇O 
• 1588424-36-5 C₂₂H₁₇F₃N₄O₄S 
• 1588424-35-4 C₁₇H₁₃ClF₂N₂O₂ 
• 1588424-34-3 C₂₇H₂₉F₃N₄O₂Si 
• 1588424-33-2 C₂₂H₂₅ClF₂N₂O₂Si 
• 1588424-32-1 C₁₆H₁₁ClF₂N₂O₂ 

Relevant articles and documents

A Facile Synthesis of New 4,6-Dichloropyridine Derivatives, Their Biological Evaluation for Antimicrobial and Antioxidant Activity, and Docking Studies

A facile synthesis of new 4,6-dichloropyridine derivatives 5(a–f), 6(a–c), and 7(a–c) were synthesized using both conventional heating and solvent-free microwave irradiation techniques. The results revealed that the latter method is superior to the conventional heating method. The easy work-up of the products, rapid reaction, and mild conditions are noticeable features of this protocol. Structural elucidation of the synthesized compounds was made on the basis of various spectroscopic methods. The synthesized compounds were evaluated for their in vitro antimicrobial activity (minimum inhibitory concentration; MIC) against various microbial strains using the agar well-diffusion method. Among the compounds, 5c showed best antimicrobial activity against most of the employed strains, especially against Staphylococcus aureus, Escherichia coli, Rhizopus arrhizus, and Candida albicans. Compounds 5a, 6a, 6c, 7a, and 7c showed significant antioxidant activity when compared to the other compounds. In addition to this, theoretical docking studies were performed for the highly potent compounds 5a, 6a, 6c, 7a, and 7c against three different drug targets belonging to the oxidoreductase family, and the results were found to be highly satisfactory.

TRICYCLIC KINASE INHIBITORS AND USE THEREOF

The present application provides novel compounds that are inhibitors of kinases, including AMPK-related kinases like NUAK1, NUAK2, SIK1, SIK2, SIK3, MARK1, MARK2, MARK3, MARK4, as well as AURKA, AURKB, AURKC, CLK1, CLK2, DCAMKL2, MAPK7, MKNK2, PIK3CD, PKN3, RET, TAOK1, TAOK2, TAOK3, ULK2 and their mutants. The application also provides compositions, including pharmaceutical compositions, kits that include compounds, and methods of making and using compounds. The compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated by these kinases.

CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME

The present disclosure relates to solid forms of N-{[2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,7]naphthyridin]-6'-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.